Kymera Therapeutics, Inc. (KYMR) Reports Q3 Loss, Misses Revenue Estimates
Kymera Therapeutics (KYMR) delivered earnings and revenue surprises of -26.76% and -89.60%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?